---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-054019"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:11:01.878398+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics CEO to present at Precision Medicine Forum Europe 2026

## Summary
- CEO Thomas Jensen will speak on May 11, 2026, in Stockholm, Sweden at Precision Medicine Forum Europe 2026.
- Presentation will cover stenoparib (2X-121), a dual PARP and WNT pathway inhibitor, and the Stenoparib DRP biomarker.
- Allarity is a Phase 2 clinical-stage company developing stenoparib for cancer; no new clinical data or financial results announced.
- A corporate presentation furnished as Exhibit 99.1 will be used in investor meetings beginning May 11, 2026.

## SEC filing metadata
- accession: 0001213900-26-054019
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390026054019/0001213900-26-054019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390026054019/ea0289893-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-054019
- JSON: https://secwatch.observer/filing/0001213900-26-054019.json
- Plain text: https://secwatch.observer/filing/0001213900-26-054019.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.